白细胞介素16在制备乳腺癌免疫治疗药物中的应用
By using interleukin-16 (IL-16) in breast cancer immunotherapy to enhance the anti-tumor effector function of CD4-positive T cells, the immunosuppression problem in the tumor microenvironment was solved, Th1 cell differentiation was promoted, and breast cancer growth was significantly inhibited, providing a new target and approach for breast cancer immunotherapy.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- ZHEJIANG UNIV
- Filing Date
- 2022-07-11
- Publication Date
- 2026-07-17
AI Technical Summary
In current breast cancer immunotherapy, the tumor microenvironment is in an immunosuppressive state, which affects the treatment effect. How can we break the immunosuppressive state by regulating the components of the tumor microenvironment and increase the proportion and activity of effector T cells?
Interleukin-16 (IL-16) was used to enhance the anti-tumor effect of CD4-positive T cells. By analyzing the Cancer Genome Atlas database and a mouse tumor-bearing model, the regulatory role of IL-16 in the immune microenvironment of breast cancer was elucidated, promoting Th1 cell differentiation and inhibiting breast cancer tumor growth.
IL-16 significantly enhances the differentiation and function of Th1 CD4+ T cells, improves the killing ability of CD8+ T cells, slows the growth of breast cancer, and provides new targets and strategies for breast cancer immunotherapy.
Smart Images
Figure CN115040639B_ABST